Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Active cancer immunotherapy faces challenges in clinical translation.
• DNA-based vaccines offer a potential strategy for cancer treatment.

Purpose of the Study:

• To evaluate the translatability of DNA-based vaccines by analyzing T-cell immunity profiles.
• To compare T-cell responses from DNA vaccination versus peptide immunization.
• To assess the efficacy of a heterologous prime-boost approach using DNA vaccines.

Main Methods:

• Murine model for plasmid vaccination.
• Transcriptome microarray analysis and flow cytometry to profile T-cell immunity.
• Dual-antigen plasmid encoding MART-1/Melan-A and tyrosinase.
• Peptide analog boost immunization.

Main Results:

• DNA vaccination induced T cells with low co-inhibitory molecule expression (e.g., PD-1), distinct from peptide immunization.
• The T-cell response showed enhanced proliferation and functional conversion to effector cells post-peptide boost.
• Peptide boost restored immunity against a subdominant tyrosinase epitope.
• Synchronous regulation of co-inhibitory molecules on T cells observed.

Conclusions:

• DNA vaccination followed by peptide boost elicits potent, broad anti-tumor immunity against multiple antigens.
• This approach enhances T-cell proliferation, effector function, and overcomes epitope dominance.
• Novel mechanism of immune homeostasis via co-inhibitory molecule regulation identified.
• DNA vaccines are promising priming agents for heterologous prime-boost cancer immunotherapies.